Can-Fite BioPharma Ltd. (CANF)
The price, the headline numbers and the latest news, in one place.
Can-Fite BioPharma Ltd. (CANF) Stock Price, Analysis & Data
| Bid | 3.35 |
| Market Cap | 7.22M |
| Revenue (ttm) | 405K |
| Net Income (ttm) | -9.83M |
| -0.04 | |
| -10.75 | |
| n/a | |
| -12.48 | |
| P/B (ttm) | 0.79 |
| P/S (ttm) | 17.83 |
| Earnings Date | Mar 27, 2020 |
| Ask | 3.4 |
| Volume | 14,890 |
| Avg. Volume (20D) | 1,436,985 |
| Open | 3.35 |
| Previous Close | 3.35 |
| Day's Range | 3.34 - 3.44 |
| 52-Week Range | 2.56 - 13.40 |
| Analyst | n/a |
| Price Target | 8 (137.39%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CANF
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cance...
Financial Performance
In 2025, Can-Fite BioPharma's revenue was 405K, a decrease of -39.91% compared to the previous year's 674K. Earnings were -9.83M, an increase of 24.72%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for CANF stock is "null". The 12-month stock price forecast is 8, which is upside of 137.39% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
